Apache Corporation (NYSE:APA) Insider Jon A. Jeppesen sold 10,145 shares of Apache stock on the open market in a transaction dated Thursday, May 29th. The shares were sold at an average price of $92.04, for a total value of $933,745.80. Following the completion of the sale, the insider now directly owns 59,640 shares of the company’s stock, valued at approximately $5,489,266. Apache Corporation (NYSE:APA) net profit margin is 11.00% and weekly performance is 3.07%. On last trading day company shares ended up $93.06. Analysts mean target price for the company is $98.41. Apache Corporation (NYSE:APA) distance from 50-day simple moving average (SMA50) is 8.55%.
Big Lots, Inc. (NYSE:BIG) reported Q1 EPS of $0.50, $0.06 better than the analyst estimate of $0.44. Revenue for the quarter came in at $1.28 billion versus the consensus estimate of $1.26 billion. Comparable store sales for stores open at least fifteen months increased 0.9% for the quarter, compared to our guidance of slightly negative to slightly positive. Big Lots sees Q2 2014 EPS of $0.24 – $0.30, versus the consensus of $0.28. Big Lots, Inc. (NYSE:BIG) shares advanced 1.24% in last trading session and ended the day on $37.51. Gross Margin is 39.00% and its return on assets is 6.80%. Big Lots, Inc. (NYSE:BIG) quarterly performance is 27.41%.
Flash-memory based storage technology vendor Nimble Storage Inc (NYSE:NMBL) this afternoon reported fiscal fiscal Q1 revenue that topped analysts’ expectations, and a smaller-than-expected net loss. Revenue in the three months ended in April more than doubled, year over year, to $46.5 million, yielding a net loss of 14 cents, excluding some costs. Analysts had been modeling $43.8 million and a 16-cent loss. Nimble Storage Inc (NYSE:NMBL) shares moved down -4.41% in last trading session and was closed at $26.88, while trading in range of $26.73 – $28.44. Nimble Storage Inc (NYSE:NMBL) year to date (YTD) performance is -40.66%.
On May 22, 2014, MacroGenics, Inc. (NASDAQ:MGNX) entered into a license and option agreement (the “Agreement”) with Takeda Pharmaceutical Company Limited (“Takeda”) for the development and commercialization of MGD010. MGD010 incorporates the Company’s proprietary platform for Dual-Affinity Re-Targeting to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently in pre-clinical development for the treatment of autoimmune diseases. MacroGenics Inc (NASDAQ:MGNX) ended the last trading day at $20.44. Company weekly volatility is calculated as 5.11% and price to cash ratio as 4.85. MacroGenics Inc (NASDAQ:MGNX) showed a positive weekly performance of 11.94%.
Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo’s zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs). Sangamo Biosciences, Inc. (NASDAQ:SGMO) net profit margin is -98.90% and weekly performance is 6.88%. On last trading day company shares ended up $13.52. Analysts mean target price for the company is $27.33. Sangamo Biosciences, Inc. (NASDAQ:SGMO) distance from 50-day simple moving average (SMA50) is -11.11%.